October 26, 2026
Dr Reddy’s fell after its second-quarter earnings and revenue missed Wall Street estimates, pressured by a sharp drop in sales of its cancer drug lenalidomide.
What happened
Dr Reddy’s Laboratories shares fell, driving a roughly 100 billion dollar move in market value, after the company reported quarterly earnings and revenue that missed analyst estimates. The miss was driven by a fall in sales of lenalidomide, a cancer drug. The company’s session ended down 1.9 percent, a move larger than what it has seen on 71 percent of trading days over the past three years.
Why it matters
The miss shows generic drugmaker revenue remains vulnerable to the pricing cycles of individual complex medicines. When a high-value drug like lenalidomide faces new competition or limits on volume, the revenue retreats quickly and hits the bottom line. The sharp stock move on a broader up day signals that the disappointment was company-specific rather than a macro event, but it raises the pressure on the rest of the generic sector to hold the line on their own key products.
The case against
A single-quarter miss on one product does not break the investment case. The broader market was calm and climbing, with small-caps outperforming large caps by 2.2 percent over the past week, which often supports risk-taking in pharma. Lenalidomide revenue was always expected to erode, and the market may have simply corrected an overly optimistic estimate in one violent session.
What settles it
Whether other generic drugmakers with significant lenalidomide exposure report similarly steep drops in their next quarters.